Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNFα inhibitory activity of two series of rolipram analogues:: Implications for a new active site model of PDE4

被引：62
|
作者：
Kleinman, EF [1 ]
Campbell, E [1 ]
Giordano, LA [1 ]
Cohan, VL [1 ]
Jenkinson, TH [1 ]
Cheng, JB [1 ]
Shirley, JT [1 ]
Pettipher, ER [1 ]
Salter, ED [1 ]
Hibbs, TA [1 ]
DiCapua, FM [1 ]
Bordner, J [1 ]
机构：
[1] Pfizer Inc, Div Cent Res, Groton, CT 06340 USA
来源：
JOURNAL OF MEDICINAL CHEMISTRY | 1998年 / 41卷 / 03期
关键词：
D O I：
10.1021/jm970685m
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
[No abstract available]
引用
收藏
页码：266 / 270
页数：5
相关论文
共 25 条
  • [1] An updated topographical model for phosphodiesterase 4 (PDE4) catalytic site
    Fossa, P
    Menozzi, G
    Mosti, L
    QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 2001, 20 (01): : 17 - 22
  • [2] Discovery of new orally active phosphodiesterase (PDE4) inhibitors
    Ochiai, H
    Ishida, A
    Ohtani, T
    Kusumi, K
    Kishikawa, K
    Yamamoto, S
    Takeda, H
    Obata, T
    Nakai, H
    Toda, M
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2004, 52 (09) : 1098 - 1104
  • [3] Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [H-3]rolipram binding
    Barnette, MS
    Bartus, JOL
    Burman, M
    Christensen, SB
    Cieslinski, LB
    Esser, KM
    Prabhakar, US
    Rush, JA
    Torphy, TJ
    BIOCHEMICAL PHARMACOLOGY, 1996, 51 (07) : 949 - 956
  • [4] Novel selective phosphodiesterase (PDE4) inhibitors.: 4.: Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones
    Van der Mey, M
    Boss, H
    Couwenberg, D
    Hatzelmann, A
    Sterk, GJ
    Goubitz, K
    Schenk, H
    Timmerman, H
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) : 2526 - 2533
  • [5] Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor
    Rock, Erin M.
    Benzaquen, Jessica
    Limebeer, Cheryl L.
    Parker, Linda A.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2009, 91 (04) : 537 - 541
  • [6] Intestinal anti-inflammatory activity of type 4 phosphodiesterase inhibitors (PDE4) in rats.
    Chevalier, E
    Chovet, M
    Jouveinal, AL
    GASTROENTEROLOGY, 1998, 114 (04) : A359 - A359
  • [7] Pharmacophore Modeling and Virtual Screening for the Discovery of New type 4 cAMP Phosphodiesterase (PDE4) Inhibitors
    Niu, Miaomiao
    Dong, Fenggong
    Tang, Shi
    Fida, Guissi
    Qin, Jingyi
    Qiu, Jiadan
    Liu, Kangbo
    Gao, Weidong
    Gu, Yueqing
    PLOS ONE, 2013, 8 (12):
  • [8] Practical synthesis of new chiral cis-phthalazinones with potential for high phosphodiesterase (PDE4) inhibitory activity
    Van Dang, Tinh
    Jin, Chung Keun
    Miyamoto, Motoyuki
    Ikee, Yoshifumi
    Masuda, Takashi
    Sano, Shigeki
    Shiro, Motoo
    Nagao, Yoshimitsu
    HETEROCYCLES, 2006, 68 (10) : 2133 - +
  • [9] Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using, [3H]-piclamilast and [3H]-rolipram
    Zhao, Y
    Zhang, HT
    O'Donnell, J
    FASEB JOURNAL, 2003, 17 (05): : A1042 - A1042
  • [10] Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]Rolipram
    Zhao, Y
    Zhang, HT
    O'Donnell, JM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (02): : 565 - 572
123